[The pharmacokinetic and toxicologic profile of 8-methoxypsoralen. The basis for safe and effective PUVA therapy].
On the basis of approximately 60 publications and in view of our own results we present a comprehensive review as to the mode of action, the pharmacokinetics, the metabolism and the toxicology of 8-methoxypsoralen (8-MOP) and its consequences in the PUVA therapy of psoriasis. The interaction of 8-MOP with DNA is presently considered to be the most likely mode of action. 8-MOP is subject to strong first-pass effects with considerable individual variations in plasma levels. An exact timing of drug dose and light dose is essential for a successful therapy, simultaneously minimizing the potential short-term and long-term risks of PUVA therapy.
Schmid
J
J
Abteilung Biochemie der Dr. Karl Thomae GmbH, Biberach an der Riss.
Brickl
R
R
Koss
F W
FW
D006801:Humans; D008730:Methoxsalen / Q000009:adverse effects* / Q000493:pharmacokinetics; D009182:Mycosis Fungoides / Q000188:drug therapy*; D011701:PUVA Therapy / Q000379:methods*; D011565:Psoriasis / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
D008730:Methoxsalen
Das pharmakokinetische und toxikologische Profil von 8-Methoxypsoralen. Die Basis für eine sichere und effektive PUVA-Therapie.